Pfizer (PFE) Stock Gains Ground on Once-Monthly Obesity Drug Breakthrough

TLDR

• Pfizer presented Phase 2b results for berobenatide, a monthly GLP-1 injection demonstrating approximately 15% weight reduction in clinical studies
• The therapy may become the first-ever monthly obesity treatment in its category, rivaling weekly alternatives such as Wegovy and Zepbound
• Over 20 clinical trials in obesity and metabolic diseases are scheduled for 2026, including 10 Phase 3 berobenatide studies
• The pharmaceutical giant struck a $10.5 billion collaboration with Innovent Biologics spanning 12 oncology treatments, requiring just $650 million upfront
• Upcoming patent expirations on Eliquis, Ibrance, and Xtandi — generating more than $20 billion in 2025 sales — pose significant dividend sustainability questions

Pfizer (PFE) stock climbed 1.36% to reach $26.04 as the pharmaceutical giant revealed aggressive expansion plans across obesity treatment, oncology, and vaccines, though its future stability depends heavily on navigating significant upcoming patent expirations.

Pfizer Inc., PFE

The most notable announcement emerged from the American Diabetes Association conference in New Orleans, where Pfizer disclosed fresh clinical data for berobenatide, its extended-duration GLP-1 receptor agonist obtained through the previous year’s $10 billion Metsera acquisition.

During the Phase 2b VESPER-1 trial, participants receiving the maximum weekly dosage experienced 15.9% body weight reduction across eight months without reaching a weight loss ceiling. Another study, VESPER-3, demonstrated that subjects administered a once-monthly dosage achieved nearly 15% weight loss throughout 14 months.

The monthly administration regimen represents the critical differentiator. Pfizer is marketing berobenatide as possibly the first monthly-interval GLP-1 therapy, directly challenging Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, which both necessitate weekly administration.

“Managing weight requires lifelong dedication, and the obstacles preventing long-term treatment adherence are equally significant as the treatment itself,” explained John B. Buse from the University of North Carolina School of Medicine.

Pfizer’s chief internal medicine officer Jim List emphasized that the medication “achieved continuous, sustained weight reduction across all dosage levels” throughout Phase 2b trials, while maintaining tolerability as subjects transitioned from weekly to monthly administration.

The pharmaceutical company intends to conduct over 20 clinical trials spanning obesity and associated conditions throughout this year, encompassing 10 active and projected Phase 3 trials for berobenatide. Geographic expansion into Chinese and Japanese markets is under consideration.

Cancer and Vaccines Fill Out the Pipeline

Pfizer is simultaneously advancing on two additional strategic directions. Within oncology, it has initiated multiple Phase 1b/2 and Phase 2 trials testing its investigational antibody-based compound PF-08634404 combined with other therapeutic agents for bladder cancer, transformed small cell lung cancer, and advanced solid tumors, partially through collaboration with Astellas.

Regarding vaccines, Pfizer has commenced enrollment for a Phase 3 clinical trial of PG4, an advanced pneumococcal conjugate vaccine formulated for infants intended to challenge or supersede its existing Prevnar 20 product.

The Innovent Biologics collaboration encompasses 12 oncology compounds spanning both organizations’ development portfolios. Pfizer is obligated to pay merely $650 million initially, with the outstanding $9.85 billion contingent upon achieving developmental, regulatory, and commercial benchmarks.

Dividend Risk Remains Real

Notwithstanding the pipeline developments, Pfizer confronts a challenging financial landscape. Last year’s revenue totaled $62.6 billion, declining substantially from the $100 billion zenith recorded in 2022. Three flagship medications — Eliquis, Ibrance, and Xtandi — encounter patent expiration next year, accounting for over $20 billion in 2025 revenue.

Outstanding long-term debt reaches $60.5 billion, generating $670 million in quarterly interest expenses. CEO Albert Bourla has projected a “five-year trajectory of high-single-digit revenue CAGR” commencing in 2029, subsequent to recent patent settlements regarding Vyndamax.

The forward dividend yield currently stands at 6.7%, simultaneously reflecting the income opportunity and the associated uncertainty.

The post Pfizer (PFE) Stock Gains Ground on Once-Monthly Obesity Drug Breakthrough appeared first on Blockonomi.